The Association between Conventional Antidepressants and the Metabolic Syndrome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  CNS Drugs

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11533280-000000000-00000PMID 20806987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Desvenlafaxine and weight change in major depressive disorder.

  2010cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction.

  2009cited by this paper
• Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting

  2009cited by this paper
• Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap

  2009cited by this paper
• Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.

  2009cited by this paper
• Glucose Tolerance in Depressed Inpatients, under Treatment with Mirtazapine and in Healthy Controls

  2009cited by this paper
• Overview of managing medical comorbidities in patients with severe mental illness.

  2009cited by this paper
• Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

  2008cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension

  2008cited by this paper
• Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study.

  2008cited by this paper
• Depression and the metabolic syndrome: gender‐dependent associations

  2008cited by this paper
• Depression, the Metabolic Syndrome and Cardiovascular Risk

  2008cited by this paper
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

  2007cited by this paper
• Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation

  2007cited by this paper
• Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males.

  2007cited by this paper
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

  2007cited by this paper
• An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

  2007cited by this paper
• The prevalence of metabolic syndrome among psychiatric inpatients in Brazil.

  2007cited by this paper
• Depression in diabetes: the chicken or the egg?

  2007cited by this paper
• Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment.

  2007cited by this paper
• High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania.

  2007cited by this paper
• A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

  2007cited by this paper
• Inflammation, Cardiovascular Disease, and Metabolic Syndrome as Sequelae of Violence Against Women

  2007cited by this paper
• Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

  2007cited by this paper
• Metabolic syndrome and depression: a cross-sectional analysis.

  2006cited by this paper
• The effect of antidepressants on lipid homeostasis: a cardiac safety concern?

  2006cited by this paper
• Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain

  2006cited by this paper
• Assessment and treatment of depression in patients with cardiovascular disease: National heart, lung, and blood institute working group report

  2006cited by this paper
• Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches

  2006cited by this paper
• Obesity and mental disorders

  2006cited by this paper
• Cortisol circadian rhythm alterations in psychotic major depression.

  2006cited by this paper
• Retrospective review of metformin in inpatients and outpatients at the University of Michigan.

  2006cited by this paper
• Effect of mirtazapine treatment on body composition and metabolism.

  2006cited by this paper
• Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine.

  2006cited by this paper
• Associations between waist circumference and depressive disorders.

  2006cited by this paper
• Recent Evidence Linking Coronary Heart Disease and Depression

  2006cited by this paper
• Changes in weight and glucose tolerance during treatment with mirtazapine.

  2006cited by this paper
• Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up.

  2006cited by this paper
• Obesity in Bipolar Disorder and Major Depressive Disorder: Results from a National Community Health Survey on Mental Health and Well-Being

  2006cited by this paper
• Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project.

  2006cited by this paper
• Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.

  2006cited by this paper
• The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms.

  2006cited by this paper
• The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms

  2006cited by this paper
• Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age

  2005cited by this paper
• Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes.

  2005cited by this paper
• A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

  2005cited by this paper
• Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.

  2005cited by this paper
• Cardiovascular effects of fluvoxamine and maprotiline in depressed patients

  2005cited by this paper
• Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

  2005cited by this paper
• Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

  2005cited by this paper
• P.2.060 Mirtazapine augmentation in the treatment of refractory depression

  2005cited by this paper
• Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

  2005cited by this paper
• Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications.

  2005cited by this paper
• Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

  2005cited by this paper
• A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

  2005cited by this paper
• A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.

  2005cited by this paper
• Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.

  2005cited by this paper
• Comparison of the Effects of Amitriptyline and Flunarizine on Weight Gain and Serum Leptin, C Peptide and Insulin Levels when used as Migraine Preventive Treatment

  2005cited by this paper
• Hypertension and depression.

  2005cited by this paper
• Depression and the Metabolic Syndrome in Young Adults: Findings From the Third National Health and Nutrition Examination Survey

  2004cited by this paper
• Lipid Metabolism and Insulin Resistance in Depressed Patients: Significance of Weight, Hypercortisolism, and Antidepressant Treatment

  2004cited by this paper
• Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment.

  2004cited by this paper
• Comparing the Effects of 8-Week Treatment With Fluoxetine and Imipramine on Fasting Blood Glucose of Patients With Major Depressive Disorder

  2004cited by this paper
• Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.

  2004cited by this paper
• Cytokines and psychopathology: lessons from interferon-alpha.

  2004cited by this paper
• Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study.

  2004cited by this paper
• Are mood disorders and obesity related? A review for the mental health professional.

  2004cited by this paper
• Screening for type 2 diabetes.

  2004cited by this paper
• Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

  2004cited by this paper
• A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

  2004cited by this paper
• Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

  2004cited by this paper
• The Metabolic Syndrome in Patients With Severe Mental Illnesses.

  2004cited by this paper
• Comorbidity in bipolar disorder: a framework for rational treatment selection

  2004cited by this paper
• Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

  2003cited by this paper
• African Women With Depression: The Effect of Imipramine and Fluoxetine on Body Mass Index and Leptin Secretion

  2003cited by this paper
• Depressive Symptoms and Metabolic Risk in Adult Male Twins Enrolled in the National Heart, Lung, and Blood Institute Twin Study

  2003cited by this paper
• The effects of mirtazapine on plasma lipid profiles in healthy subjects.

  2003cited by this paper
• Glucose dysregulation and mirtazapine-induced weight gain.

  2003cited by this paper
• Increased cholesterol levels during paroxetine administration in healthy men.

  2003cited by this paper
• Mood disorders and allostatic load.

  2003cited by this paper
• Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors

  2003cited by this paper
• Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial

  2003cited by this paper
• Mortality of patients with mood disorders: follow-up over 34-38 years.

  2002cited by this paper
• Immune dysregulation in major depression: a critical review of existing evidence.

  2002cited by this paper
• Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes.

  2002cited by this paper
• The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?

  2002cited by this paper
• Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

  2002cited by this paper
• Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.

  2002cited by this paper
• Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

  2002cited by this paper
• Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions

  2002cited by this paper
• Antidepressant Side Effects in Depression Patients Treated in a Naturalistic Setting: A Study of Bupropion, Moclobemide, Paroxetine, Sertraline, and Venlafaxine

  2002cited by this paper
• Hypercortisolemic Depression Is Associated With Increased Intra-Abdominal Fat

  2002cited by this paper
• Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.

  2002cited by this paper
• Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases.

  2002cited by this paper
• Sertraline treatment of major depression in patients with acute MI or unstable angina.

  2002cited by this paper
• Depression and immune function: central pathways to morbidity and mortality.

  2002cited by this paper

• The effect of bright light therapy on glycemic control and cortisol rhythmicity in depression: a randomized controlled trial.

  2026cites this paper
• Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

  2025cites this paper
• Impact of Psychiatric Comorbidities on Healthcare Resource Utilization in Patients Undergoing Venous Sinus Stenting for Idiopathic Intracranial Hypertension.

  2025cites this paper
• Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use

  2025cites this paper
• Practice and proficiency of Isha Yoga for better mental health outcomes: insights from a COVID-19 survey

  2024cites this paper
• Dyslipidemia among psychiatric patients with depression – common possible reasons and treatment implications – review

  2024cites this paper
• Clinical Patterns of Metabolic Syndrome in First-Hospitalized Major Depressive Disorder Patients: Comparison of Antidepressant-Exposed and Drug-Naïve Groups

  2024cites this paper
• Longitudinal trajectories of metabolic and inflammatory markers in youth with emerging mood disorders

  2024cites this paper
• Identifying influencing factors of metabolic syndrome in patients with major depressive disorder: A real-world study with Bayesian network modeling.

  2024cites this paper
• Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men

  2023cites this paper
• A systematic review of randomized controlled trials assessing the effect of Vortioxetine on metabolic syndrome risk indicators in patients with depression

  2023cites this paper
• Is There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?

  2023cites this paper
• Metabolic Effects of Antidepressants: Results of a Randomized Study’s Interim Analysis

  2023cites this paper
• RISCO DE MORTE SÚBITA CARDÍACA E EFEITOS ADVERSOS CARDIOVASCULARES ASSOCIADOS AO USO DE ANTIDEPRESSIVOS

  2023cites this paper
• Exercise Promotion Practices among Mental Health Professionals: A Scoping Review

  2023cites this paper
• Risk of antidepressant initiation among users of cardiovascular agents and metformin.

  2023cites this paper
• Metabolic disorders induced by psychotropic drugs.

  2023cites this paper
• Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome

  2023cites this paper
• Psychiatric Comorbidities in Patients With Idiopathic Intracranial Hypertension

  2022cites this paper
• Neurobiological Mechanisms Modulating Emotionality, Cognition and Reward-Related Behaviour in High-Fat Diet-Fed Rodents

  2022cites this paper
• Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway

  2022cites this paper
• Allostatic load and systemic comorbidities in psychiatric disorders.

  2022cites this paper
• Prevalence, awareness, treatment, and control of diabetes mellitus by depressive symptom severity: a cross-sectional analysis of NHANES 2011–2016

  2021cites this paper
• The effect of non-pharmacological interventions on psychological stress and quality of life of parents of children with retinoblastoma

  2021cites this paper
• Increased prevalence of metabolic syndrome in patients with bipolar disorder compared to a selected control group-a Northern Netherlands LifeLines population cohort study.

  2021cites this paper
• Adiposity in Depression or Depression in Adiposity? The Role of Immune-Inflammatory-Microbial Overlap

  2021cites this paper
• P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes

  2020cites this paper
• Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls.

  2020cites this paper
• The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet

  2019cites this paper
• Frequency of Breast feeding among working women of Multan.

  2019cites this paper
• Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable?

  2018cites this paper
• Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness

  2018cites this paper
• Increased Risk of Metabolic Syndrome in Antidepressants Users: A Mini Review

  2018cites this paper
• The Antidepressants and the Metabolic Syndrome

  2018cites this paper
• Between mood and matter: studies on the interface between mood disorders and physical conditions

  2018cites this paper
• Wenlafaksyna – właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej Venlafaxine – pharmacology and application in clinical practice

  2018cites this paper
• Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder.

  2017cites this paper
• Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: A cross-sectional study.

  2017cites this paper
• The interface of depression and obesity.

  2017cites this paper
• Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.

  2017cites this paper
• Shared metabolic and immune‐inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders

  2017cites this paper
• Epigenetic Mechanisms and Treatments of Fetal Alcohol Exposure-Induced Memory Impairment and Metabolic Dysregulation

  2017cites this paper
• Effects of Shambhavi Mahamudra Kriya, a Multicomponent Breath-Based Yogic Practice (Pranayama), on Perceived Stress and General Well-Being

  2017cites this paper
• Serum Apelin And Nesfatin-1 Levels in Depression Patients and Their Relationship with Treatment

  2017cites this paper
• WHEN THE HEART ACHES: ATYPICAL FEATURES IN DEPRESSION ARE A HALLMARK OF AN INCREASED CARDIO- METABOLIC RISK Lasserre Aurélie Lasserre Aurélie, 2017, WHEN THE HEART ACHES: ATYPICAL FEATURES IN DEPRESSION ARE A HALLMARK OF AN INCREASED CARDIO-METABOLIC RISK

  2017cites this paper
• Effects of Shambhavi Mahamudra Kriya , a Multicomponent Breath-Based Yogic Practice ( Pranayama ), on Perceived Stress and General Well-Being

  2017cites this paper
• Metabolic syndrome in first‐time hospitalized patients with depression: a 1‐year follow‐up study

  2016cites this paper
• Antidepressant Drugs in Elderly

  2016cites this paper
• Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: the Maine-Syracuse Study

  2016cites this paper
• BIDIRECTIONAL PROSPECTIVE ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH DEPRESSION, ANXIETY, AND ANTIDEPRESSANT USE

  2016cites this paper
• Metabolic syndrome and central obesity in depression: A cross-sectional study

  2016cites this paper
• Depressive symptoms are associated with worsened severity of the metabolic syndrome in African American women independent of lifestyle factors: A consideration of mechanistic links from the Jackson heart study.

  2016cites this paper
• Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings

  2016cites this paper
• Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants

  2016cites this paper
• Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study

  2016cites this paper
• Étude des relations entre syndrome métabolique, maladies psychiatriques et psychotropes : revue de la littérature

  2016influential citation
• A systematic review of randomised control trials on the effects of yoga on stress measures and mood.

  2015cites this paper
• Metabolic Syndrome Among People with PTSD: Epidemiological Overview

  2015cites this paper
• Pathophysiologic Aspects of Hypertension

  2015cites this paper
• Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.

  2015cites this paper
• Major depressive disorder and diabetes: does serotonin bridge the gap?

  2015cites this paper
• Metabolic syndrome and physical activity in patients with first-episode schizophrenia

  2015cites this paper
• Genomic medicine and risk prediction across the disease spectrum

  2015cites this paper
• Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder.

  2015cites this paper
• Immunology, Inflammation, Mental Disorders, and Cardiovascular Risk

  2015cites this paper
• The metabolic syndrome and related characteristics in major depression: inpatients and outpatients compared: metabolic differences across treatment settings.

  2014influential citation
• Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population

  2014cites this paper
• Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.

  2014cites this paper
• Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression.

  2014cites this paper
• Assessment of body composition using bioelectrical impedance in patients with schizophrenia – preliminary report

  2014cites this paper
• Comparison of metabolic parameters and Framingham cardiovascular risk scores before and after in‐hospital treatment with antipsychotics

  2014cites this paper
• Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.

  2014cites this paper
• Changes of Body Weight and Metabolic Syndrome in Psychiatric Inpatients

  2014cites this paper
• Second-generation antipsychotics in the treatment of major depressive disorder: current evidence

  2013cites this paper
• Four-Year Analysis of Cardiovascular Disease Risk Factors, Depression Symptoms, and Antidepressant Medicine Use in the Look AHEAD (Action for Health in Diabetes) Clinical Trial of Weight Loss in Diabetes

  2013cites this paper
• The Association of Antidepressant Medication and Body Weight Gain

  2013cites this paper
• Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients

  2013cites this paper
• Agomelatine as monotherapy for major depression: an outpatient, open-label study

  2013cites this paper
• Veränderungen des Lipoproteinprofils unter kurzzeitiger Mirtazapineinnahme bei gesunden Probanden

  2013cites this paper
• Metabolic Syndrome in Drug-naïve Patients with Depressive Disorders

  2013cites this paper
• Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables

  2013cites this paper
• The effect of escitalopram on metabolic parameters in patients with major depressive disorder, generalised anxiety disorder, and panic disorder: a prospective 6-month follow-up study.

  2013cites this paper
• Effect of metabolic abnormalities on cognitive performance and clinical symptoms in schizophrenia

  2013cites this paper
• Antidepressant-Antianxiety Agents

  2013cites this paper
• Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome.

  2012cites this paper
• Glucose metabolism and antidepressant medication.

  2012cites this paper
• Metabolic syndrome in relation to psychotropic polypharmacy

  2012cites this paper
• Resolution of Depression & Quality of Life Improvements in a Patient with Major Depressi ve Disorder after Hemisphere Specific Stimulation: A Case Study

  2012influential citation
• METABOLIC SYNDROME IN RELATION TO PSYCHOTROPIC POLYPHARMACY

  2012cites this paper
• Risque cardiométabolique, affections psychiatriques et antipsychotiques

  2012cites this paper
• Association Between Depression and Metabolic Syndrome A systematic review and meta-analysis of epidemiological studies

  2012cites this paper
• Cardiometabole risicofactoren, psychiatrische stoornissen en antipsychotische medicatie

  2012cites this paper
• Reduced serum levels of adiponectin in elderly patients with major depression.

  2012cites this paper
• A systematic review and meta-analysis of epidemiological studies

  2012cites this paper
• Clinical use of antidepressant therapy and associated cardiovascular risk

  2012cites this paper
• The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.

  2012cites this paper
• Comorbidity of Depression and Diabetes: In a Nutshell

  2012cites this paper
• Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity.

  2012cites this paper
• Biological Alterations in Depression

  2011cites this paper
• Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology

  2011cites this paper